Rhumatologie. Une nouvelle option thérapeutique dans la prise en charge de l'inflammation chronique en rhumatologie: les inhibiteurs des janus kinases [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].

Details

Serval ID
serval:BIB_67CDAECEFF08
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Rhumatologie. Une nouvelle option thérapeutique dans la prise en charge de l'inflammation chronique en rhumatologie: les inhibiteurs des janus kinases [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Journal
Revue Médicale Suisse
Author(s)
Varisco P.A., So A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2014
Volume
10
Number
414
Pages
187-191
Language
french
Notes
Publication types: English Abstract ; Journal Article Publication Status: ppublish
Abstract
In the last 15 years, the therapeutical options for the treatment of chronic inflammatory diseases in rheumatology have increased a lot. Nevertheless, some patients do not respond or respond partially to the current therapies--including to the biologics therapy. Tofacitinib (Xeljanz) is now on the Swiss market. It inhibits the JAK pathway. Tofacitinib--as monotherapy or with methotrexate--improves the control of rheumatoid arthritis (RA). In a comparative study, tofacitinib was as effective as adalimumab. Further, tofacitinib reduced structural damages in RA and is considered as an alternative, in case of non-response, to anti-TNF and probably to other biologics therapy. The side effects are upper respiratory tract and opportunist infections and tuberculosis. Blood count, lipids, kidney function, liver tests, CK and blood pressure have to be monitored.
Keywords
Antirheumatic Agents/adverse effects, Antirheumatic Agents/pharmacology, Arthritis, Rheumatoid/drug therapy, Arthritis, Rheumatoid/enzymology, Chronic Disease, Drug Approval, Humans, Inflammation/drug therapy, Inflammation/enzymology, Janus Kinases/antagonists & inhibitors, Piperidines/adverse effects, Piperidines/pharmacology, Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/pharmacology, Pyrimidines/adverse effects, Pyrimidines/pharmacology, Pyrroles/adverse effects, Pyrroles/pharmacology, Rheumatic Diseases/drug therapy, Rheumatic Diseases/enzymology, hic" UI="D013557">Switzerland
Pubmed
Create date
15/01/2015 12:14
Last modification date
20/08/2019 14:23
Usage data